Clinical impact of CD5 expression in Korean patients with diffuse large B-cell lymphoma

Hyun-Young Kim; Mi-Ae Jang; Hee-Jin Kim; Seok Jin Kim; Won Seog Kim; Sun-Hee Kim

doi:10.5045/br.2017.52.3.193

Quick links

Most Cited Most Read Ahead of Print Archives Go to E-submission

Original Article

Split Viewer

Blood Res 2017; 52(3):

Published online September 25, 2017

https://doi.org/10.5045/br.2017.52.3.193

Clinical impact of CD5 expression in Korean patients with diffuse large B-cell lymphoma

Hyun-Young Kim^1,2, Mi-Ae Jang³, Hee-Jin Kim¹, Seok Jin Kim⁴, Won Seog Kim⁴, and Sun-Hee Kim^1*

Author Info. +

¹Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

²Department of Laboratory Medicine, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine, Jinju, Korea.

³Department of Laboratory Medicine and Genetics, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea.

⁴Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Correspondence to : Sun-Hee Kim, M.D., Ph.D. Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea. sunnyhk@skku.edu

Received: April 3, 2017; Revised: June 2, 2017; Accepted: June 17, 2017

Abstract

Go to

Abstract

Background

CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) accounts for 5?10% of DLBCL cases and has poor patient outcomes. However, most studies on CD5+ DLBCL were performed in Japanese patients and only few data are available for Korean population. In this study, we investigated the clinical characteristics and prognostic impact of CD5 expression in Korean patients with bone marrow (BM) involvement of DLBCL.

Methods

Patients who were initially diagnosed with BM involvement of de novo DLBCL from 2005 to 2013 were included. Clinicopathological features and outcomes of patients were compared between CD5+ and CD5 negative (CD5?) DLBCL.

Results

Among a total of 57 patients, the number of patients with CD5+ and CD5? DLBCL were 13 and 44, respectively. Clinical and laboratory features of CD5+ DLBCL were not significantly different from those of CD5? DLBCL. The 3-year overall survival (OS) rates for CD5+ and CD5? DLBCL were 20.2% and 59.0%, respectively (P=0.031), and 3-year progression-free survival (PFS) rates for CD5+ and CD5? DLBCL were 23.1% and 50.1%, respectively (P=0.055).

Conclusion

CD5+ DLBCL with BM involvement showed an inferior survival tendency compared to CD5? DLBCL, and thorough evaluation of CD5 expression might be helpful to predict the prognosis of patients with DLBCL.

Keywords Diffuse large B-cell lymphoma, CD5, Bone marrow, Korea

Article

Original Article

Blood Res 2017; 52(3): 193-199

Published online September 25, 2017 https://doi.org/10.5045/br.2017.52.3.193

Clinical impact of CD5 expression in Korean patients with diffuse large B-cell lymphoma

Hyun-Young Kim^1,2, Mi-Ae Jang³, Hee-Jin Kim¹, Seok Jin Kim⁴, Won Seog Kim⁴, and Sun-Hee Kim^1*

¹Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

²Department of Laboratory Medicine, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine, Jinju, Korea.

³Department of Laboratory Medicine and Genetics, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea.

⁴Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Correspondence to:Sun-Hee Kim, M.D., Ph.D. Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea. sunnyhk@skku.edu

Received: April 3, 2017; Revised: June 2, 2017; Accepted: June 17, 2017

Abstract

Background

Methods

Results

Conclusion

CD5+ DLBCL with BM involvement showed an inferior survival tendency compared to CD5? DLBCL, and thorough evaluation of CD5 expression might be helpful to predict the prognosis of patients with DLBCL.

Keywords: Diffuse large B-cell lymphoma, CD5, Bone marrow, Korea

Abstract

Fig 1.

Download

Figure 1.

Kaplan-Meier plots for the overall survival (OS) and progression-free survival (PFS) in de novo diffuse large B cell lymphoma. Median OS was not reached, and median PFS was 14 months.

Blood Research 2017; 52: 193-199https://doi.org/10.5045/br.2017.52.3.193

Fig 2.

Download

Figure 2.

Kaplan-Meier plots for the (A) overall survival and (B) progression-free survival in de novo diffuse large B cell lymphoma according to CD5 expression.

Blood Research 2017; 52: 193-199https://doi.org/10.5045/br.2017.52.3.193

Table 1 . Demographic and clinical characteristics of 57 patients with bone marrow involvement of de novo diffuse large B cell lymphoma (DLBCL)..

^a)P-values are from the comparison of the CD5+ and CD5− DLBCL groups..

Abbreviations: BM, bone marrow; CD5−, CD5 negative; CD5+, CD5 positive; CNS, central nervous system; GCB, germinal center B-cell like; IPI, international prognostic index; LDH, serum lactate dehydrogenase..